• AZD0156 (SKU B7822): Reliable ATM Kinase Inhibition in Cance

  2026-06-03

  This article addresses real-world lab challenges in DNA damage response assays and metabolic vulnerability studies, showcasing how AZD0156 (SKU B7822) offers validated, reproducible solutions. With reference to APExBIO's high-purity product, it provides scenario-driven guidance on protocol optimization, data interpretation, and product selection for ATM kinase inhibition workflows.

• Refining In Vitro Drug Response Evaluation in Cancer Researc

  2026-06-03

  Schwartz's dissertation systematically distinguishes between relative and fractional viability in assessing anti-cancer drug responses in vitro. By clarifying how proliferation arrest and cell death contribute differently to drug efficacy, the work advances methodological rigor and interpretability for cancer pharmacology.

• Methyl-β-cyclodextrin: Practical Guidance for Membrane Extra

  2026-06-02

  Methyl-β-cyclodextrin (SKU C6939) selectively extracts cholesterol and modulates membrane fluidity in cell-based and biochemical experiments. It should be used strictly for research workflows investigating membrane organization and cholesterol-dependent signaling pathways, and is not intended for diagnostic or clinical applications.

• Firefly Luciferase mRNA: Optimizing Reporter Assays with ARC

  2026-06-02

  Firefly Luciferase mRNA (ARCA, 5mCTP, ΨUTP) delivers unmatched stability and translational efficiency, redefining the sensitivity and reproducibility of gene expression and cell viability assays. This article bridges the latest LNP formulation strategies with hands-on protocols, empowering researchers to achieve robust, bioluminescent readouts even in challenging experimental contexts.

• PF-562271 HCl: Precision FAK/Pyk2 Inhibitor for Tumor Growth

  2026-06-01

  PF-562271 HCl is redefining FAK/Pyk2 pathway interrogation with unmatched selectivity, supporting advanced cancer research and therapy resistance studies. This guide details robust workflows, practical troubleshooting, and actionable insights for maximizing reproducibility in tumor growth inhibition and metastatic modeling.

• Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibi

  2026-06-01

  Anlotinib hydrochloride enables robust, reproducible inhibition of angiogenesis and tumor proliferation through multi-kinase targeting. This guide details advanced experimental workflows, practical troubleshooting, and comparative advantages that empower researchers to rigorously dissect the ERK signaling pathway and endothelial cell dynamics using APExBIO’s validated compound.

• Dabigatran Etexilate: Direct Thrombin Inhibitor in Coagulati

  2026-05-31

  Dabigatran etexilate empowers advanced anticoagulant research through its potent, selective inhibition of thrombin and oral prodrug profile, enabling both in vitro and in vivo models with reduced workflow complexity. This guide details practical protocols, troubleshooting, and comparative insights for researchers leveraging APExBIO’s high-purity compound.

• NHE1 in Macrophages Drives Octanal/Olfr2-Induced Atheroscler

  2026-05-30

  This study demonstrates that sodium-hydrogen exchanger 1 (NHE1) in macrophages is a critical downstream mediator of atherosclerosis progression triggered by octanal-activated Olfr2. By elucidating the calcium-dependent mechanisms linking Olfr2 activation to NLRP3 inflammasome-driven inflammation, the work highlights NHE1 as a promising target for modulating cardiovascular disease.

• Hypoxia-Driven EGFR Inhibitor Resistance via FGFR1 and MAPK

  2026-05-29

  This study demonstrates that hypoxia induces resistance to EGFR inhibitors in non-small cell lung cancer by upregulating FGFR1 and activating the MAPK pathway. The findings highlight MEK pathway inhibition, including with Trametinib, as a promising strategy to overcome this resistance in preclinical models.

• Mitocytosis Inhibition Enhances Mitochondrial Drug Delivery

  2026-05-29

  The reference study uncovers how targeting mitocytosis—a process that expels damaged mitochondria via migrasomes—can improve the effectiveness of mitochondria-targeted therapies in metastatic breast cancer models. By engineering a dual-targeting nanoplatform that both damages mitochondria and blocks mitocytosis, the researchers demonstrate a significant advance in overcoming resistance mechanisms to antimetastatic treatment.

• Targeting EDI3 in HER2+ Breast Cancer Resistant to Therapy

  2026-05-28

  Keller et al. identified EDI3 as a novel vulnerability in ER-HER2+ breast cancer cells that are resistant to HER2-targeted therapies. Their findings demonstrate that EDI3 inhibition, either by silencing or pharmacological means, reduces cell viability and tumor growth, suggesting EDI3 as a promising therapeutic target in this difficult-to-treat cancer subtype.

• Abiraterone Acetate: Potent CYP17 Inhibitor for Prostate Can

  2026-05-28

  Abiraterone acetate is a selective CYP17 inhibitor and 3β-acetate prodrug of abiraterone, extensively used in prostate cancer research. It irreversibly blocks androgen biosynthesis, exhibits superior potency to ketoconazole, and demonstrates dose-dependent androgen receptor inhibition in cell-based and in vivo models.

• Zolmitriptan as a 5-HT1B Receptor Agonist: Protocols & Innov

  2026-05-27

  Unlock advanced migraine and cluster headache research with high-purity Zolmitriptan, a selective 5-HT1B receptor agonist. This guide delivers step-by-step experimental workflows, troubleshooting insights, and cross-domain applications, leveraging the latest lysosomal biogenesis findings to optimize serotonin receptor pharmacology.

• CK2 and ERK8 Inhibitor: Mechanism and Research Benchmarks

  2026-05-27

  The CK2 and ERK8 inhibitor (2-(4,5,6,7-tetrabromo-2-(dimethylamino)-1H-benzo[d]imidazol-1-yl)acetic acid) is a potent small molecule inhibitor for protein kinase research. It modulates phosphorylation in key cellular pathways and serves as a robust biochemical reagent for enzyme interaction studies. Evidence highlights its high purity, DMSO solubility, and value in protein condensate research.

• Patient-Derived 3D Spheroids Advance Prostate Cancer Modelin

  2026-05-26

  This study establishes and characterizes patient-derived 3D spheroid cultures from radical prostatectomy specimens as a versatile translational model for organ-confined prostate cancer. The findings demonstrate the viability, cellular composition, and drug response of these spheroids, providing a robust platform for preclinical prostate cancer research and pharmacological testing.

15968 records 1/1065 page Next 12345 下5页 Last page